[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,721,618
  • Shares Outstanding, K 51,624
  • Annual Sales, $ 190,410 K
  • Annual Income, $ 20,890 K
  • EBIT $ 9 M
  • EBITDA $ 11 M
  • 60-Month Beta -2.81
  • Price/Sales 14.32
  • Price/Cash Flow 123.68
  • Price/Book 6.30

Options Overview Details

View History
  • Implied Volatility 14.72% (-0.59%)
  • Historical Volatility 92.68%
  • IV Percentile 2%
  • IV Rank 0.45%
  • IV High 124.05% on 10/20/25
  • IV Low 14.23% on 04/20/26
  • Expected Move (DTE 18) 0.04 (0.08%)
  • Put/Call Vol Ratio 2.89
  • Today's Volume 140
  • Volume Avg (30-Day) 9,142
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 152,914
  • Open Int (30-Day) 119,132
  • Expected Range 52.68 to 52.76

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.73
  • Number of Estimates 6
  • High Estimate $0.93
  • Low Estimate $0.62
  • Prior Year $-0.95
  • Growth Rate Est. (year over year) +176.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.78 +77.08%
on 03/30/26
52.88 -0.27%
on 04/24/26
+22.69 (+75.49%)
since 03/27/26
3-Month
29.43 +79.19%
on 03/27/26
52.88 -0.27%
on 04/24/26
+9.58 (+22.18%)
since 01/27/26
52-Week
29.43 +79.19%
on 03/27/26
90.32 -41.61%
on 07/09/25
-20.53 (-28.02%)
since 04/25/25

Most Recent Stories

More News
SLNO Deadline: Rosen Law Firm Urges Soleno Therapeutics, Inc. (NASDAQ: SLNO) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025...

SLNO : 52.75 (+0.06%)
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

NEW YORK and NEW ORLEANS , April 24, 2026 /PRNewswire/ -- Kahn Swick & Foti , LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ...

SLNO : 52.75 (+0.06%)
INVESTOR NOTICE: Soleno Therapeutics (SLNO) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action- Hagens Berman

SAN FRANCISCO , April 23, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class...

SLNO : 52.75 (+0.06%)
Are WSR, SLNO, OMEX, AVNS Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

OMEX : 0.9215 (+0.16%)
AVNS : 24.62 (-0.16%)
WSR : 18.91 (-0.21%)
SLNO : 52.75 (+0.06%)
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Drug Safety Risks: SueWallSt

Important Notice Regarding Alleged DCCR Safety Data Misrepresentations

SLNO : 52.75 (+0.06%)
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK , April 22, 2026 /PRNewswire/ --

SLNO : 52.75 (+0.06%)
Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , April 22, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

SLNO : 52.75 (+0.06%)
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Post-Launch Safety Crisis: Levi & Korsinsky

From Optimism to Disillusionment: How Investor Sentiment Shifted

SLNO : 52.75 (+0.06%)
SLNO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Soleno To Contact Him Directly To Discuss Their Options

SLNO : 52.75 (+0.06%)
SLNO Investor Alert: Soleno Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Hyperphagia Drug Launch Disruptions - Hagens Berman

SAN FRANCISCO , April 21, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman reminds investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) of the pending securities class...

SLNO : 52.75 (+0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 53.01
2nd Resistance Point 52.95
1st Resistance Point 52.83
Last Price 52.75
1st Support Level 52.65
2nd Support Level 52.59
3rd Support Level 52.47

See More

52-Week High 90.32
Fibonacci 61.8% 67.06
Fibonacci 50% 59.87
Last Price 52.75
Fibonacci 38.2% 52.69
52-Week Low 29.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.